TVRD

SEC source: 0001209191-22-013986 · doc4.xml · nonDerivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 171,565

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-22-013986 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,679

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-22-013988 · doc4.xml · derivative · entry 2

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 121,000

Underlying: Common Stock · 121,000 shares

Expires 2032-02-25

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on March 25, 2022, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-22-013988 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · President and CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 203,037

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of February 25, 2023, February 25, 2024 and February 25, 2025, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-21-070808 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 58,507

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest as to (i) 50% on December 15, 2022; and (ii) 50% on June 15, 2023, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-21-070801 · doc4.xml · nonDerivative · entry 1

Reilly Thomas Charles · CIK 0001827590 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,522

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest as to (i) 50% on December 15, 2022; and (ii) 50% on June 15, 2023, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-21-070816 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 153,679

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest as to (i) 50% on December 15, 2022; and (ii) 50% on June 15, 2023, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-21-070805 · doc4.xml · nonDerivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,412

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest as to (i) 50% on December 15, 2022; and (ii) 50% on June 15, 2023, subject to the Reporting Person's continued service with the Issuer through each such vesting date.

SEC source: 0001209191-21-064855 · doc4.xml · nonDerivative · entry 1

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,200

SEC source: 0001209191-21-062727 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 45,900

F1 · kind: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021.

SEC source: 0001209191-21-062593 · doc4.xml · derivative · entry 3

Posner Christopher · CIK 0001748265 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 566,000

Underlying: Common Stock · 566,000 shares

Expires 2031-10-29

F3 · derivative.exercise_date: 25% of the shares will vest and become exercisable on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date. These options were granted to the Reporting Person pursuant to the Employment Agreement.

SEC source: 0001209191-21-062593 · doc4.xml · nonDerivative · entry 2

Posner Christopher · CIK 0001748265 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 164,037

F2 · shares: Represents the number of shares underlying RSUs granted to the Reporting Person pursuant to the Employment Agreement. Each RSU represents the contingent right to receive one share of common stock of the Issuer. 25% of the RSUs will vest on October 29, 2022 and the remainder will vest over the following 12 equal quarterly installments, in each case, subject to the Reporting Person's continued service to the Issuer as of each such date.

SEC source: 0001209191-21-062593 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director · Senior Advisor

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,037

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to an Employment Agreement, dated October 29, 2021, between the Reporting Person and the Issuer, whereby the Reporting Person is employed as a Senior Advisor to the Issuer effective October 29, 2021 and as President and Chief Executive Officer of the Issuer effective November 9, 2021 (the "Employment Agreement"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs will vest in full on March 31, 2022, subject to the Reporting Person's continued service to the Issuer on such date.

SEC source: 0001209191-21-061953 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,900

F1 · kind: These shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 13, 2021.

SEC source: 0001209191-21-055304 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 991,405

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.34 to $15.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-21-054300 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,011,405

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-054301 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 47,900

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-054304 · doc4.xml · nonDerivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 70,917

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-054303 · doc4.xml · nonDerivative · entry 1

Reilly Thomas Charles · CIK 0001827590 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,352

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on June 14, 2021 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-054302 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,072

F1 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs reported in the Form 4 filed with the Securities and Exchange Commission on August 26, 2021, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-053534 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,019,845

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-053536 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,010

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of two possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-053538 · doc4.xml · nonDerivative · entry 1

Reilly Thomas Charles · CIK 0001827590 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,334

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-053537 · doc4.xml · nonDerivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 72,676

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of three possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-053535 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,919

F1 · shares: Represents the number of shares that vested under a performance-based restricted stock unit award (the "RSU") based on the Issuer's satisfaction of certain performance criteria of the award. In light of the performance-based vesting conditions of the award, such shares were not reportable under Section 16 until vesting was determined, which occurred on August 24, 2021. The vested shares represents the first of two possible vesting events of the total number of shares subject to the award. The remaining shares subject to the award will vest only upon the satisfaction of additional performance vesting criteria. Each RSU represents the contingent right to receive one share of common stock of the Issuer.

SEC source: 0001209191-21-038766 · doc4.xml · nonDerivative · entry 2

VOGELBAUM MARTIN · CIK 0001237624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,160

F2 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on June 3, 2021. The sales were effected pursuant to a "sell-to-cover" arrangement adopted in accordance with Rule 10b5-1 on May 28, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.11, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-21-038764 · doc4.xml · nonDerivative · entry 2

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 16,096

F2 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on June 3, 2021. The sales were effected pursuant to a "sell-to-cover" arrangement adopted in accordance with Rule 10b5-1 on May 28, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.99 to $13.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-21-038760 · doc4.xml · nonDerivative · entry 2

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,380

F2 · shares: Represents the number of shares sold by the Reporting Person to satisfy the Reporting Person's tax obligations resulting from the settlement of vested RSUs on June 3, 2021. The sales were effected pursuant to a "sell-to-cover" arrangement adopted in accordance with Rule 10b5-1 on May 28, 2021.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.02 to $13.10, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-21-038765 · doc4.xml · derivative · entry 2

Shiff Susan Ph.D. · CIK 0001811463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2031-06-03

F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038765 · doc4.xml · nonDerivative · entry 1

Shiff Susan Ph.D. · CIK 0001811463 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,200

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's nonemployee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038766 · doc4.xml · derivative · entry 3

VOGELBAUM MARTIN · CIK 0001237624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,600

Underlying: Common Stock · 21,600 shares

Expires 2031-06-03

F4 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038766 · doc4.xml · nonDerivative · entry 1

VOGELBAUM MARTIN · CIK 0001237624 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 28,800

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038759 · doc4.xml · derivative · entry 2

BAINS HARRISON M JR · CIK 0001202282 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2031-06-03

F2 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038759 · doc4.xml · nonDerivative · entry 1

BAINS HARRISON M JR · CIK 0001202282 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,400

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038764 · doc4.xml · derivative · entry 3

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2031-06-03

F4 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038764 · doc4.xml · nonDerivative · entry 1

Posner Christopher · CIK 0001748265 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,400

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038760 · doc4.xml · derivative · entry 3

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,800

Underlying: Common Stock · 10,800 shares

Expires 2031-06-03

F4 · derivative.exercise_date: This option was granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. The shares underlying the option vest and become exercisable on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-038760 · doc4.xml · nonDerivative · entry 1

Ives Jeffrey L. · CIK 0001614096 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 17,900

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs") granted to the Reporting Person pursuant to the Issuer's non-employee director compensation policy. Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest on the earlier of (i) June 3, 2022 and (ii) immediately prior to the Issuer's next annual meeting of stockholders following the grant date, in each case, subject to the Reporting Person's continued service as a director through such date.

SEC source: 0001209191-21-028141 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,610

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019 and amended on August 19, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.41 - $28.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

SEC source: 0001209191-21-024294 · doc4.xml · derivative · entry 2

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 103,000

Underlying: Common Stock · 103,000 shares

Expires 2031-03-30

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 30, 2021, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-21-024294 · doc4.xml · nonDerivative · entry 1

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,002,511

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of March 30, 2022, March 30, 2023 and March 30, 2024, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-21-024296 · doc4.xml · derivative · entry 2

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2031-03-30

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 30,2021, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-21-024296 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,610

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of March 30, 2022, March 30, 2023 and March 30, 2024, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-21-024299 · doc4.xml · derivative · entry 2

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2031-03-30

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 30, 2021, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-21-024299 · doc4.xml · nonDerivative · entry 1

Terrillion Scott · CIK 0001706426 · Sec'y; Chief Compliance & G.C.

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 67,342

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of March 30, 2022, March 30, 2023 and March 30, 2024, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-21-024298 · doc4.xml · derivative · entry 2

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 32,000

Underlying: Common Stock · 32,000 shares

Expires 2031-03-30

F2 · derivative.exercise_date: The shares shall vest and become exercisable in a series of 48 successive equal monthly installments beginning on April 30, 2021, in each case subject to the Reporting Person's continued service as of each such date.

SEC source: 0001209191-21-024298 · doc4.xml · nonDerivative · entry 1

Menzaghi Frederique Ph.D. · CIK 0001597152 · Chief Scientific Off,SVP-R&D

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 135,319

F1 · shares: Represents the number of shares underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of common stock of the Issuer. The RSUs vest in three equal annual installments on each of March 30, 2022, March 30, 2023 and March 30, 2024, in each case, subject to the Reporting Person's continued service (as that term is defined in the Issuer's 2014 Equity Incentive Plan) as of each such date.

SEC source: 0001209191-21-022913 · doc4.xml · nonDerivative · entry 1

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 30,610

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on November 15, 2019, as amended on August 19, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.36 to $19.87, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

SEC source: 0001209191-21-018644 · doc4.xml · nonDerivative · entry 2

CHALMERS DEREK T · CIK 0001166287 · Director · President & CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 950,511

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on September 6, 2018 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.

SEC source: 0001209191-21-018646 · doc4.xml · nonDerivative · entry 2

Goncalves Joana · CIK 0001756991 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,610

F2 · kind: This sale was effected pursuant to a "sell to cover" arrangement adopted by the Reporting Person in accordance with Rule 10b5-1 on March 12, 2020 to satisfy the tax withholding obligations triggered by the vesting of RSUs, and does not represent a discretionary trade by the Reporting Person.